Literature DB >> 26748492

Unprovoked venous thromboembolism and subsequent cancer risk: a population-based cohort study.

L-M Sun1, W-S Chung2,3,4, C-L Lin5,6, J-A Liang7,8, C-H Kao7,9.   

Abstract

UNLABELLED: ESSENTIALS: A relationship between unprovoked venous thromboembolism (VTE) and cancer risk was investigated. We collected 27,751 VTE patients and compared them with 110,409 frequency-matched people without VTE. This cohort study showed significantly higher risks of overall and site-specific cancers in the VTE group. There is an increased risk in the first 6 months after VTE, and VTE can be an indicator of occult cancer.
BACKGROUND: We investigated the relationship between unprovoked venous thromboembolism (VTE) and subsequent cancer risk in Taiwan, focusing on both short-term and long-term cancer development.
METHODS: For the case group, we obtained data on 27,751 patients diagnosed with unprovoked VTE between 1 January 1998, and 31 December 2008. For the comparison group, four people without unprovoked VTE were frequency-matched with each unprovoked VTE patient according to age, sex, and index year. Cox proportional hazards regression models were employed to determine the effects of unprovoked VTE on cancer risk.
RESULTS: Overall cancer risk was significantly higher in the unprovoked VTE group than in the comparison group (adjusted hazard ratio = 2.26, 95% confidence interval = 2.16-2.37). The increased risk was observed in both men and women in various age groups. The patients in the unprovoked VTE group showed a significantly increased risk of cancer at all site-specific cancer sites. Analyses stratified according to follow-up duration revealed that significant differences were more evident between the two groups over a follow-up duration of < 0.5 years than over a follow-up duration of ≥ 3 years. Furthermore, the 1-year mortality risk of cancer patients with unprovoked VTE was significantly higher than that for cancer patients in the non-VTE group.
CONCLUSION: The results of this study show that unprovoked VTE is associated with a consistently high risk of subsequent cancer diagnosis. This is particularly true in the first 6 months after VTE. It suggests that unprovoked VTE can be an indicator of occult malignancy.
© 2016 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  ICD-9; cohort study; neoplasms; risk; venous thromboembolism

Mesh:

Year:  2016        PMID: 26748492     DOI: 10.1111/jth.13251

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  7 in total

Review 1.  Subclavian Effort Thrombosis: Pathophysiology, Diagnosis, and Management.

Authors:  Eric C King; Roger E Goldman; Matthew Schwenke; Amir A Sarkeshik
Journal:  Semin Intervent Radiol       Date:  2022-08-31       Impact factor: 1.780

2.  Deep venous thrombosis as the single sign of unexpected metastatic urinary tract cancer in a patient with a history of cutaneous melanoma: A case report.

Authors:  Joachim Mikkelsen; Steen Henrik Matzen
Journal:  Int J Surg Case Rep       Date:  2016-10-14

3.  Bidirectional risk between venous thromboembolism and cancer in East Asian patients: synthesis of evidence from recent population-based epidemiological studies.

Authors:  Victor C Kok
Journal:  Cancer Manag Res       Date:  2017-12-05       Impact factor: 3.989

Review 4.  Cancer-associated thrombosis in Asia.

Authors:  Pantep Angchaisuksiri
Journal:  Thromb J       Date:  2016-10-04

5.  Cancer Screening in Patients with Unprovoked Thromboembolism: How to do it and Who Benefits?

Authors:  Filipa Ferreira; José Pereira; Ana Lynce; José Nunes Marques; Ana Martins
Journal:  Cureus       Date:  2020-02-10

6.  Epidemiology of Cancer-Associated Thrombosis in Asia: A Systematic Review.

Authors:  Lai Heng Lee; Chandramouli Nagarajan; Chuen Wen Tan; Heng Joo Ng
Journal:  Front Cardiovasc Med       Date:  2021-05-21

7.  Venous thromboembolism and cancer risk.

Authors:  Per Sandén; Peter J Svensson; Anders Själander
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.